Allergy

>

Latest News

Study of Intranasal Epinephrine Powder (NS002) Published in Prestigious International Journal, Nasus Pharma Ltd Says / image credit ©MQ-Illustrations/stock.adobe.com
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission

June 3rd 2025

Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.

Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose / image credit: ©New Africa/AdobeStock
Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose

March 28th 2025

Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study / image credit ©Andrey Popov/AdobeStock
Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study

March 26th 2025

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

March 24th 2025

Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis / image credit ©tashatuvango/stock.adobe.com
Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis

March 18th 2025

Latest CME Events & Activities

Community Practice Connections™: Navigating a New Era of Food Allergy Management

View More

<1234
© 2025 MJH Life Sciences

All rights reserved.